#Canada #Calgary #Infectious Diseases #Mario Savarese #Rapid Infection

Rapid Infection Diagnostics Welcomes Mario Savarese to Advisory Board

Calgary, AB — Rapid Infection Diagnostics Inc. (RID), a prominent Canadian life sciences firm, has made waves with the announcement that Mario Savarese is joining its Strategic Advisory Board. Known for his groundbreaking work in clinical microbiology, Savarese brings over two decades of experience in technology innovation and strategic growth. Before joining RID, he served as the CEO, Chief Strategic Officer, and Head of R&D at Copan WASP, where he played a crucial role in scaling the business tenfold.

Savarese's extensive background not only encompasses strategic insights but also deep technical expertise—qualities that are essential as RID aims to revolutionize the landscape of infectious disease diagnostics. Ian Lewis, the Founder and CEO of RID, noted Savarese’s unique combination of knowledge in microbiology, technology leadership, and business acumen as pivotal for the company's future.

“Mario brings a rare combination of deep microbiology expertise, technology leadership, and business experience,” said Lewis. “His work at the intersection of laboratory operations and emerging technologies positions him perfectly to help translate innovation into scalable clinical solutions.”

In his new role, Savarese will guide RID in its ambition to enhance its product offerings and commercialization strategies. His expertise in AI and robotics, alongside his experience in building strategic partnerships and global product development, will be crucial for RID’s efforts to implement rapid pathogen identification and antimicrobial susceptibility testing technologies.

Savarese emphasized the importance of not just scientific innovation but also understanding the environment where new solutions must operate. “Transforming microbiology requires more than scientific innovation; it requires an understanding of the environment in which new technologies must ultimately be adopted and the ability to translate innovation into practical, scalable solutions,” he explained. “I am excited to contribute to RID’s vision and help the team navigate that journey.”

About Rapid Infection Diagnostics Inc.

RID is committed to creating cutting-edge technologies aimed at transforming infectious disease diagnostics. Leveraging advanced mass spectrometry and metabolomics, the company’s tools provide rapid pathogen identification and antimicrobial susceptibility testing, significantly shortening the waiting time from days to hours. RID’s vision revolves around delivering actionable insights faster, thereby supporting timely, data-driven decisions in the treatment of infectious diseases. For more information on RID, visit Rapid Infection Diagnostics.